Correlation Between Citigroup and AptaBio Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Citigroup and AptaBio Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citigroup and AptaBio Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Citigroup and AptaBio Therapeutics, you can compare the effects of market volatilities on Citigroup and AptaBio Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citigroup with a short position of AptaBio Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citigroup and AptaBio Therapeutics.

Diversification Opportunities for Citigroup and AptaBio Therapeutics

-0.82
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Citigroup and AptaBio is -0.82. Overlapping area represents the amount of risk that can be diversified away by holding Citigroup and AptaBio Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AptaBio Therapeutics and Citigroup is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citigroup are associated (or correlated) with AptaBio Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AptaBio Therapeutics has no effect on the direction of Citigroup i.e., Citigroup and AptaBio Therapeutics go up and down completely randomly.

Pair Corralation between Citigroup and AptaBio Therapeutics

Taking into account the 90-day investment horizon Citigroup is expected to generate 0.34 times more return on investment than AptaBio Therapeutics. However, Citigroup is 2.92 times less risky than AptaBio Therapeutics. It trades about 0.08 of its potential returns per unit of risk. AptaBio Therapeutics is currently generating about -0.01 per unit of risk. If you would invest  4,525  in Citigroup on August 31, 2024 and sell it today you would earn a total of  2,562  from holding Citigroup or generate 56.62% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy97.06%
ValuesDaily Returns

Citigroup  vs.  AptaBio Therapeutics

 Performance 
       Timeline  
Citigroup 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Citigroup are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating fundamental indicators, Citigroup exhibited solid returns over the last few months and may actually be approaching a breakup point.
AptaBio Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days AptaBio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Citigroup and AptaBio Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Citigroup and AptaBio Therapeutics

The main advantage of trading using opposite Citigroup and AptaBio Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citigroup position performs unexpectedly, AptaBio Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AptaBio Therapeutics will offset losses from the drop in AptaBio Therapeutics' long position.
The idea behind Citigroup and AptaBio Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format